Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethylenediamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylenediamine SCHEMBL11226382 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CA1CA2TSHRCA12 | |
| Putrescine SCHEMBL10842435 | 0.92 | CYP2C9 (0.49) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL11546476 | 0.92 | CYP2C9 (0.49) | ALDH1A1CA1CA2TSHRCA12 | |
| Propylamine SCHEMBL6911004 | 0.92 | CYP2C9 (0.49) | ALDH1A1CA1CA2TSHRCA12 | |
| Monoethanolamine SCHEMBL1274858 | 0.92 | CYP2C9 (0.49) | ALDH1A1CA1CA2TSHRCA12 | |
| Ethylamine SCHEMBL3808345 | 0.91 | ALDH1A1 (0.52) | ALDH1A1CA1CA2TSHRCA12 | |
| Acetic Acid SCHEMBL29405595 | 0.91 | CYP2C9 (0.49) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL8981419 | 0.90 | CYP2C9 (0.48) | ALDH1A1CA1CA2TSHRCA12 | |
| Cysteamine SCHEMBL714691 | 0.90 | CYP2C9 (0.48) | ALDH1A1CA1CA2TSHRCA12 | |
| Hydrazine SCHEMBL8861759 | 0.89 | ALDH1A1 (0.58) | ALDH1A1CA1CA2TSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106433994-B | Method for preparing biodiesel by polymerizing ionic liquid catalysis | 河北工程大学 | 2021-04-02 | — | — | CN | claimed |
| EP-0379483-B1 | 1,2,3,4,10,14b-HEXAHYDRODIBENZO c,f]PYRAZINO- 1,2-a]AZEPINO DERIVATIVES | UNIV MONASH (AU) | 1999-12-29 | — | — | EP | claimed |
| JP-11071373-A | — | — | None | — | — | JP | disclosed |
| CN-106433994-B | Method for preparing biodiesel by polymerizing ionic liquid catalysis | 河北工程大学 | 2021-04-02 | — | — | CN | disclosed |
| EP-2834233-B1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORP (FI) | 2018-04-25 | — | — | EP | disclosed |
| US-9249127-B2 | Alpha2 adrenoceptor agonists | ORION CORPORATION (FI) | 2016-02-02 | — | — | US | disclosed |
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2015-03-05 | — | — | US | disclosed |
| US-20120208019-A1 | CARBON FIBER BUNDLE AND METHOD FOR PRODUCING SAME | MITSUBISHI RAYON CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| EP-2476799-A1 | CARBON FIBER BUNDLE AND METHOD FOR PRODUCING SAME | Mitsubishi Rayon Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-4250186-A | ADMINISTERING A 2-(SUBSTITUTED PHENYL-IMINO)-IMIDAZOLIDINE COMPOUND | BOEHRINGER INGELHEIM GMBH (DE) | 1981-02-10 | — | — | US | disclosed |
| US-4136188-A | TREATMENT OF DIABETES WITH 2-SUBSTITUTED-1,3-DIAZACYCLIC COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1979-01-23 | — | — | US | disclosed |
| US-4081544-A | ANTIDEPRESSANTS | SCHERING CORPORATION (US) | 1978-03-28 | — | — | US | disclosed |
| US-4065569-A | Use of 2-imidazolines as hypoglycemic agents | SCHERING CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4018765-A | HETEROCYCLIC | HOFFMANN-LA ROCHE INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3992403-A | 2-Imidazolines and their use as hypoglycemic agents | SCHERING CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
| US-3949076-A | GASTRIC ACID SECRETION INHIBITION | SMITHKLINE CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3932431-A | ANTIDEPRESSANT, ANTIINFLAMMATORY | SCHERING CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
| US-3931217-A | ANALGESIC, PSYCHOSTIMULANT | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ADRA2A, ADRB2, ADRA2C | ALDH1A1 465/4885CA1 4190/4885CA2 1765/4885 |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | ALDH1A1 1716/4885CA1 4534/4885CA2 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.